Celastrol attenuates sodium oxalate-induced acute kidney injury and crystal deposition by inhibiting NF-κB
Basic Medicine|更新时间:2025-04-14
|
Celastrol attenuates sodium oxalate-induced acute kidney injury and crystal deposition by inhibiting NF-κB
Journal of Army Medical UniversityVol. 47, Issue 7, Pages: 691-700(2025)
作者机构:
1.重庆医科大学附属第二医院泌尿肾病中心,重庆
2.;陆军军医大学(第三军医大学):基础医学院免疫学教研室,重庆
3.陆军军医大学(第三军医大学):第一附属医院第九五八医院肾病泌尿科,重庆
作者简介:
XU Guilian, E-mail: xuguilian2004@163.com
ZHANG Keqin, E-mail: zhkq2004@163.com
基金信息:
Founder: Supported by the General Project of Natural Science Foundation of Chongqing(CSTB2022NSCQ-MSX0099);the Scientific Research Cultivation Project for Undergraduates of Army Medical University(2024XBK24)
LIU Yiheng,ZHENG Quanyou,ZHANG Wanyuan,et al.Celastrol attenuates sodium oxalate-induced acute kidney injury and crystal deposition by inhibiting NF-κB[J].J Army Med Univ,2025,47(07):691-700.
LIU Yiheng,ZHENG Quanyou,ZHANG Wanyuan,et al.Celastrol attenuates sodium oxalate-induced acute kidney injury and crystal deposition by inhibiting NF-κB[J].J Army Med Univ,2025,47(07):691-700.DOI:10.16016/j.2097-0927.202501070.
Celastrol attenuates sodium oxalate-induced acute kidney injury and crystal deposition by inhibiting NF-κB
Objective To investigate the role and possible mechanism of celastrol (Cel) in sodium oxalate (NaOx)-induced acute kidney injury (AKI) and crystal deposition in the kidney tissues in mice. Methods Male C57BL/6 mice (aged 8~12 weeks
weighing 22~24 g) were randomly divided into 3 groups. Saline group (control group
intraperitoneal injection with normal saline and drinking water freely)
NaOx group (injured group
intraperitoneal injection of 75 mg/kg NaOx
and drinking water containing 50 μmol/L NaOx)
and NaOx+Cel group (treatment group
intraperitoneal injection of 1 mg/kg Cel firstly and then 75 mg/kg NaOx in 24 h later
drinking water containing 50 μmol/L NaOx). All specimens were collected in 24 h after NaOx injection. HK-2 cells were randomly divided into 4 groups: Medium group (no treatment)
NaOx group (500 μmol/L NaOx)
NaOx+Cel group (400 nmol/L Cel pre-treatment for 2 h followed by 500 μmol/L NaOx treatment)
and NaOx+Cel+BA group [8 μmol/L betulinic acid (BA
NF-κB agonist) after the interventions as the NaOx+Cel group
]
. Cells of each group were collected in 24 h after corresponding treatments. Von Koosa and cell adhesion assays were used to observe crystal deposition. HE staining was employed to observe renal histopathology and score the damage. CCK-8 assay was utilized to detect cell viability to obtain the optimal concentrations of NaOx and Cel. Serum urea and creatinine levels were detected. Immunohisotochemical assay was conducted to detect the expression of OPN
CD44
KIM-1
NGAL
p65
IL-1β
BAX
and Caspase-3
and Western blotting was performed for protein levels of OPN
CD44
KIM-1
p65
P-p65 and IL-1β. Results The mice in the NaOx+Cel group showed reduced crystal deposition (
P
<
0.0001)
attenuated renal tubular damage (
P
<
0.01)
decreased serum urea and creatinine levels (
P
<
0.05)
and declined expression levels of the renal adhesion molecules OPN and CD44
the kidney injury molecules KIM-1 and NGAL
the inflammation-associated molecules p65 and IL-1β
and the apoptosis related molecules BAX and Caspase-3 when compared with the NaOx group (
P
<
0.05). In
in vitro
study
the NaOx+Cel group showed reduced crystal adhesion (
P
<
0.0001)
decreased expression of the adhesion molecules OPN and CD44 (
P
<
0.05)
down-regulation of the inflammatory molecule IL-1β and P-p65/p65 ratio (
P
<
0.05)
and down-regulation of the renal injury molecule KIM-1 (
P
<
0.05) when compared with the NaOx group. In the NaOx+Cel+BA group
crystal adhesion was significantly increased (
P
<
0.0001)
the inflammatory molecule IL-1β and the ratio of P-p65/p65 were increased (
P
<
0.05)
and the kidney injury molecule KIM-1 was increased when compared with the NaOx+Cel group (
P
<
0.05). Conclusion Cel may reduce NaOx-induced crystal deposition and AKI by inhibiting NF-κB activation.
关键词
Keywords
references
SKOLARIKOS A , SOMANI B , NEISIUS A , et al . Metabolic evaluation and recurrence prevention for urinary stone patients: an EAU guidelines update [J]. Eur Urol , 2024 , 86 ( 4 ): 343 - 363 . DOI: 10.1016/j.eururo.2024.05.029 http://dx.doi.org/10.1016/j.eururo.2024.05.029 .
HUANG L X , CHEN W , TAN Z J , et al . Mrc1 + macrophage-derived IGF1 mitigates crystal nephropathy by promoting renal tubule cell proliferation via the AKT/Rb signaling pathway [J]. Theranostics , 2024 , 14 ( 4 ): 1764 - 1780 . DOI: 10.7150/thno.89174 http://dx.doi.org/10.7150/thno.89174 .
MULAY S R , HONARPISHEH M M , FORESTO-NETO O , et al . Mitochondria permeability transition versus necroptosis in oxalate-induced AKI [J]. J Am Soc Nephrol , 2019 , 30 ( 10 ): 1857 - 1869 . DOI: 10.1681/ASN.2018121218 http://dx.doi.org/10.1681/ASN.2018121218 .
KHAN S R , CANALES B K , DOMINGUEZ-GUTIERREZ P R . Randall’s plaque and calcium oxalate stone formation: role for immunity and inflammation [J]. Nat Rev Nephrol , 2021 , 17 ( 6 ): 417 - 433 . DOI: 10.1038/s41581-020-00392-1 http://dx.doi.org/10.1038/s41581-020-00392-1 .
SETTHAWONG V , SRISUBAT A , POTISAT S , et al . Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy (PCNL) or retrograde intrarenal surgery (RIRS) for kidney stones [J]. Cochrane Database Syst Rev , 2023 , 8 ( 8 ): CD007044 . DOI: 10.1002/14651858.CD007044 http://dx.doi.org/10.1002/14651858.CD007044 .
DHAYAT N A , BONNY O , ROTH B , et al . Hydrochlorothiazide and prevention of kidney-stone recurrence [J]. N Engl J Med , 2023 , 388 ( 9 ): 781 - 791 . DOI: 10.1056/NEJMoa2209275 http://dx.doi.org/10.1056/NEJMoa2209275 .
LAN Y , ZHU W , DUAN X L , et al . Glycine suppresses kidney calcium oxalate crystal depositions via regulating urinary excretions of oxalate and citrate [J]. J Cell Physiol , 2021 , 236 ( 10 ): 6824 - 6835 . DOI: 10.1002/jcp.30370 http://dx.doi.org/10.1002/jcp.30370 .
NG S W , CHAN Y H , CHELLAPPAN D K , et al . Molecular modulators of celastrol as the keystones for its diverse pharmacological activities [J]. Biomed Pharmacother , 2019 , 109 : 1785 - 1792 . DOI: 10.1016/j.biopha.2018.11.051 http://dx.doi.org/10.1016/j.biopha.2018.11.051 .
WANG C , DAI S , ZHAO X T , et al . Celastrol as an emerging anticancer agent: Current status, challenges and therapeutic strategies [J]. Biomed Pharmacother , 2023 , 163 : 114882 . DOI: 10.1016/j.biopha.2023.114882 http://dx.doi.org/10.1016/j.biopha.2023.114882 .
SHIRAI T , NAKAI A , ANDO E , et al . Celastrol suppresses humoral immune responses and autoimmunity by targeting the COMMD3/8 complex [J]. Sci Immunol , 2023 , 8 ( 81 ): eadc9324 . DOI: 10.1126/sciimmunol.adc9324 http://dx.doi.org/10.1126/sciimmunol.adc9324 .
XU S H , FENG Y Q , HE W S , et al . Celastrol in metabolic diseases: Progress and application prospects [J]. Pharmacol Res , 2021 , 167 : 105572 . DOI: 10.1016/j.phrs.2021.105572 http://dx.doi.org/10.1016/j.phrs.2021.105572 .
PAN M L , WANG Z , WANG Y Y , et al . Celastrol alleviated acute kidney injury by inhibition of ferroptosis through Nrf2/GPX4 pathway [J]. Biomed Pharmacother , 2023 , 166 : 115333 . DOI: 10.1016/j.biopha.2023.115333 http://dx.doi.org/10.1016/j.biopha.2023.115333 .
NIRUMAND M C , HAJIALYANI M , RAHIMI R , et al . Dietary plants for the prevention and management of kidney stones: preclinical and clinical evidence and molecular mechanisms [J]. Int J Mol Sci , 2018 , 19 ( 3 ): 765 . DOI: 10.3390/ijms19030765 http://dx.doi.org/10.3390/ijms19030765 .
MOE O W . Kidney stones: pathophysiology and medical management [J]. Lancet , 2006 , 367 ( 9507 ): 333 - 344 . DOI: 10.1016/S0140-6736(06)68071-9 http://dx.doi.org/10.1016/S0140-6736(06)68071-9 .
SUN X Y , OUYANG J M , YU K . Shape-dependent cellular toxicity on renal epithelial cells and stone risk of calcium oxalate dihydrate crystals [J]. Sci Rep , 2017 , 7 ( 1 ): 7250 . DOI: 10.1038/s41598-017-07598-7 http://dx.doi.org/10.1038/s41598-017-07598-7 .
COE F L , WORCESTER E M , EVAN A P . Idiopathic hypercalciuria and formation of calcium renal stones [J]. Nat Rev Nephrol , 2016 , 12 ( 9 ): 519 - 533 . DOI: 10.1038/nrneph.2016.101 http://dx.doi.org/10.1038/nrneph.2016.101 .
YUAN P , SUN X F , LIU X , et al . Kaempferol alleviates calcium oxalate crystal-induced renal injury and crystal deposition via regulation of the AR/NOX2 signaling pathway [J]. Phytomedicine , 2021 , 86 : 153555 . DOI: 10.1016/j.phymed.2021.153555 http://dx.doi.org/10.1016/j.phymed.2021.153555 .
LI Y H , ZHANG J , LIU H Y , et al . Curcumin ameliorates glyoxylate-induced calcium oxalate deposition and renal injuries in mice [J]. Phytomedicine , 2019 , 61 : 152861 . DOI: 10.1016/j.phymed.2019.152861 http://dx.doi.org/10.1016/j.phymed.2019.152861 .
SHENG X X , WARD M D , WESSON J A . Crystal surface adhesion explains the pathological activity of calcium oxalate hydrates in kidney stone formation [J]. J Am Soc Nephrol , 2005 , 16 ( 7 ): 1904 - 1908 . DOI: 10.1681/ASN. 2005040400 http://dx.doi.org/10.1681/ASN.2005040400 .
MA Q Y , STEIGER S . Neutrophils and extracellular traps in crystal-associated diseases [J]. Trends Mol Med , 2024 , 30 ( 9 ): 809 - 823 . DOI: 10.1016/j.molmed.2024.05.010 http://dx.doi.org/10.1016/j.molmed.2024.05.010 .
MING S X , TIAN J , MA K , et al . Oxalate-induced apoptosis through ERS-ROS-NF-κB signalling pathway in renal tubular epithelial cell [J]. Mol Med , 2022 , 28 ( 1 ): 88 . DOI: 10.1186/s10020-022-00494-5 http://dx.doi.org/10.1186/s10020-022-00494-5 .
DEMOULIN N , AYDIN S , GILLION V , et al . Pathophysiology and management of hyperoxaluria and oxalate nephropathy: a review [J]. Am J Kidney Dis , 2022 , 79 ( 5 ): 717 - 727 . DOI: 10.1053/j.ajkd.2021.07.018 http://dx.doi.org/10.1053/j.ajkd.2021.07.018 .
Effects of baicalin on expression of mucin 5AC and cystic fibrosis transmembrane conductance regulator in airway epithelium through NF-κB signaling pathway
Naringin improves lipopolysaccharide-induced depression-like behaviors in mice
DcR2 expression in renal tissue and urine after ischemia reperfusion related to kidney injury in rats
Protective effects of 6-formylindolo[3,2-b]carbazole against LPS-induced acute respiratory distress syndrome in rats
Related Author
DENG Jiezhong
YANG Yusheng
HE Jinyue
LUO Fei
XU Jianzhong
ZHANG Zehua
ZHANG Yan1
ZHANG Caili1
Related Institution
Department of Orthopedic Surgery, First Affiliated Hospital, Army Medical University (Third Military Medical University)
Zhengzhou Key Laboratory of Integrated Traditional Chinese and Western Medicine for the Prevention and Treatment of Brain Cognitive Diseases, Zhengzhou,Hena province
Henan Engineering Technology Research Center for Prevention and Treatment of Brain Cognitive Diseases with Integrated Traditional Chinese and Western Medicine
Henan Key Laboratory of Traditional Chinese Medicine Syndrome and Prescription in Signaling, Henan International Joint Laboratory of TCM Syndrome and Prescription in Signaling, Academy of Chinese Medicine, Henan University of Chinese Medicine
Department of Military Cognitive Psychology, Faculty of Medical Psychology, Army Medical University (Third Military Medical University)